# A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)

> **NCT01976091** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Limb-Girdle Muscular Dystrophy, Type 2D

## Interventions

- **GENETIC:** SRP-9004

## Key facts

- **NCT ID:** NCT01976091
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-01
- **Primary completion:** 2019-03-14
- **Final completion:** 2019-03-14
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01976091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01976091, "A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01976091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*